It´s with pride, that pharm-analyt announces the purchase of the new generation mass-spec-system QTRAP® 6500 with SelexION system from AB Sciex!

We are looking forward to meeting you at the highly effective partnering conference "Bio-Europe Spring 2013", held in Barcelona in the time between March 11-13th 2013!

We will be delighted to meet with you in a one-to-one partnering meeting or informally at one of the receptions!
And there´s always the opportunity of chatting over a real Austrian cup of coffee and some Mozart-chocolate at the Austrian booth "LISA"! Sounds good?

See you in Barcelona!

After submitting european patents for lysosomal storage deseases in 2011 (Gaucher) and 2012 (NPC) in December last year we submitted another patent for a marker for MLD!

All three markers have remarkably high sensitivity as well as specificity.
pharm-analyt is continuously investigating in biomarkers, predominantly Small Molecules in plasma.

We´re looking forward to meeting many old acquaintances again and sure to meet many new people as we participate once more in the Bio-Europe conference in Hamburg!

See you soon!

"A short bioanalytical feasibility is the most efficient way preparing optimally for first in-vivo studies" was the message of the presentation given by Christian Kikuta and Martin van Dam.
The afternoon was dedicated to the subject "Preparing for 1st In-Man / Preclinical Strategies", organized by LISA, the Austrian life science cluster organization.

In the early phase of developing a compound obviously the bioanalytical behavior is vastly unknown. Yet the upcoming TOX or Dose Range Finding Study want to be planned optimally, in the light of the large lumps of budget absorbed by them.

A bioanalytical feasibility is a 2-4 day ballpark investigation of the bioanalytical behavior in plasma (or respective matrices). Output are rudimentary data on: stability in plasma, detectability, linearity, rough limits of detection and selectivity.

In combination with a pilot pre-clinical study administering the compound to 2-3 rodents, even important first information on bioavailibility can be gained, such as first-pass-effect, metabolism or protein binding.

The benefits are obvious:
- Reduction of Risk and disclosing latent "bad news"
- Estimation of effort and cost for upcoming in vivo trials
- Knowing scope of data to expect of pre-clinics
- Improved position towards VCs and authorities

In context with in-vivo pilot study:
- Pre-conclustions on administrative route
- Impression of bioavailibility / metabolism
- Orientation for dose range

Summary: Cut Risk and Cost with Preliminary Data.